Information SRX3207 is an orally active dual inhibitor ofSyk-PI3Kwith IC50 of 39.9 nM, 31200 nM, 3070 nM, 3070 nM, 244 nM, 388 nM, 9790 nM forSyk,Zap70,BRD41,BRD42,PI3K alpha,PI3K delta,PI3K gamma, respectively. SRX3207 blocks tumor immunosuppression and increases anti-tumor immunity. Targets Syk (cell-free assay); PI3K alpha (cell-free assay); PI3K delta (cell-free assay); BRD41 (cell-free assay); BRD42 (cell-free assay) 32131,39.9 nM; 244 nM; 388 nM; 3070 nM; 3070 nM In vivo SRX3207 blocks both PI3K and Syk in MΦs thereby activating innate and adaptive antitumor immunity in vivo.